Posted by Michael Wonder on 10 Jun 2025
SNT-5505 awarded US FDA fast track designation
10 June 2025 - Syntara today announces that its lead candidate, SNT-5505, has been granted fast track designation by the US FDA for the treatment of patients with myelofibrosis with an inadequate response to JAK inhibitor therapy.
SNT-5505 represents a novel therapeutic approach by inhibiting lysyl oxidases, key enzymes in fibrosis and growth factor signalling pathways.
